| Literature DB >> 26499378 |
Mrinmoy Sanyal1, Marie Morimoto2, Alireza Baradaran-Heravi3, Kunho Choi2, Neeraja Kambham4, Kent Jensen5, Suparna Dutt5, Kira Y Dionis-Petersen6, Lan Xiang Liu6, Katie Felix7, Christy Mayfield8, Benjamin Dekel9, Arend Bokenkamp10, Helen Fryssira11, Encarna Guillen-Navarro12, Giuliana Lama13, Milena Brugnara14, Thomas Lücke15, Ann Haskins Olney16, Tracy E Hunley17, Ayse Ipek Polat18, Uluc Yis18, Radovan Bogdanovic19, Katarina Mitrovic19, Susan Berry20, Lydia Najera20, Behzad Najafian21, Mattia Gentile22, C Nur Semerci23, Michel Tsimaratos24, David B Lewis6, Cornelius F Boerkoel25.
Abstract
Schimke immuno-osseous dysplasia (SIOD) is an autosomal recessive, fatal childhood disorder associated with skeletal dysplasia, renal dysfunction, and T-cell immunodeficiency. This disease is linked to biallelic loss-of-function mutations of the SMARCAL1 gene. Although recurrent infection, due to T-cell deficiency, is a leading cause of morbidity and mortality, the etiology of the T-cell immunodeficiency is unclear. Here, we demonstrate that the T cells of SIOD patients have undetectable levels of protein and mRNA for the IL-7 receptor alpha chain (IL7Rα) and are unresponsive to stimulation with IL-7, indicating a loss of functional receptor. No pathogenic mutations were detected in the exons of IL7R in these patients; however, CpG sites in the IL7R promoter were hypermethylated in SIOD T cells. We propose therefore that the lack of IL7Rα expression, associated with hypermethylation of the IL7R promoter, in T cells and possibly their earlier progenitors, restricts T-cell development in SIOD patients.Entities:
Keywords: CD127; CpG; IL7Rα; Promoter DNA methylation; SIOD; T-cell immunodeficiency
Mesh:
Substances:
Year: 2015 PMID: 26499378 DOI: 10.1016/j.clim.2015.10.005
Source DB: PubMed Journal: Clin Immunol ISSN: 1521-6616 Impact factor: 3.969